587 related articles for article (PubMed ID: 29775690)
1. Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.
Wang W; Kandimalla R; Huang H; Zhu L; Li Y; Gao F; Goel A; Wang X
Semin Cancer Biol; 2019 Apr; 55():37-52. PubMed ID: 29775690
[TBL] [Abstract][Full Text] [Related]
2. Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.
Włodarczyk M; Włodarczyk J; Siwiński P; Sobolewska-Włodarczyk A; Fichna J
Curr Drug Targets; 2018; 19(15):1731-1737. PubMed ID: 30073926
[TBL] [Abstract][Full Text] [Related]
3. Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer.
Bramsen JB; Rasmussen MH; Ongen H; Mattesen TB; Ørntoft MW; Árnadóttir SS; Sandoval J; Laguna T; Vang S; Øster B; Lamy P; Madsen MR; Laurberg S; Esteller M; Dermitzakis ET; Ørntoft TF; Andersen CL
Cell Rep; 2017 May; 19(6):1268-1280. PubMed ID: 28494874
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer subtypes: Translation to routine clinical pathology.
Roseweir AK; McMillan DC; Horgan PG; Edwards J
Cancer Treat Rev; 2017 Jun; 57():1-7. PubMed ID: 28505475
[TBL] [Abstract][Full Text] [Related]
5. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2014; ():91-9. PubMed ID: 24857065
[TBL] [Abstract][Full Text] [Related]
6. Back to the Colorectal Cancer Consensus Molecular Subtype Future.
Menter DG; Davis JS; Broom BM; Overman MJ; Morris J; Kopetz S
Curr Gastroenterol Rep; 2019 Jan; 21(2):5. PubMed ID: 30701321
[TBL] [Abstract][Full Text] [Related]
7. Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation.
Fessler E; Medema JP
Trends Cancer; 2016 Sep; 2(9):505-518. PubMed ID: 28741479
[TBL] [Abstract][Full Text] [Related]
8. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer.
Eilertsen IA; Moosavi SH; Strømme JM; Nesbakken A; Johannessen B; Lothe RA; Sveen A
Cancer Lett; 2020 Jan; 469():246-255. PubMed ID: 31678167
[TBL] [Abstract][Full Text] [Related]
9. Proteome Heterogeneity in Colorectal Cancer.
Lim LC; Lim YM
Proteomics; 2018 Feb; 18(3-4):. PubMed ID: 29316255
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of mutated genes and mutational processes reveals novel mutational biomarkers in colorectal cancer.
Dashti H; Dehzangi I; Bayati M; Breen J; Beheshti A; Lovell N; Rabiee HR; Alinejad-Rokny H
BMC Bioinformatics; 2022 Apr; 23(1):138. PubMed ID: 35439935
[TBL] [Abstract][Full Text] [Related]
11. Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer.
Kagawa H; Hatakeyama K; Shiomi A; Hino H; Manabe S; Yamaoka Y; Nagashima T; Ohshima K; Urakami K; Yamaguchi K
Biomed Res; 2022; 43(6):201-209. PubMed ID: 36517022
[TBL] [Abstract][Full Text] [Related]
12. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.
Akkad J; Bochum S; Martens UM
Langenbecks Arch Surg; 2015 Feb; 400(2):129-43. PubMed ID: 25701352
[TBL] [Abstract][Full Text] [Related]
13. Integrative analysis from multi-centre studies identifies a function-derived personalized multi-gene signature of outcome in colorectal cancer.
Sun J; Zhao H; Lin S; Bao S; Zhang Y; Su J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):5270-5281. PubMed ID: 31140730
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
15. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
Schlicker A; Beran G; Chresta CM; McWalter G; Pritchard A; Weston S; Runswick S; Davenport S; Heathcote K; Castro DA; Orphanides G; French T; Wessels LF
BMC Med Genomics; 2012 Dec; 5():66. PubMed ID: 23272949
[TBL] [Abstract][Full Text] [Related]
16. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic and proteomic intra-tumor heterogeneity of colorectal cancer varies depending on tumor location within the colorectum.
Árnadóttir SS; Mattesen TB; Vang S; Madsen MR; Madsen AH; Birkbak NJ; Bramsen JB; Andersen CL
PLoS One; 2020; 15(12):e0241148. PubMed ID: 33332369
[TBL] [Abstract][Full Text] [Related]
18. Molecular Insights Into Colorectal Carcinoma.
Requena DO; Garcia-Buitrago M
Arch Med Res; 2020 Nov; 51(8):839-844. PubMed ID: 32962865
[TBL] [Abstract][Full Text] [Related]
19. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.
Das V; Kalita J; Pal M
Biomed Pharmacother; 2017 Mar; 87():8-19. PubMed ID: 28040600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
